000301292 001__ 301292
000301292 005__ 20250515113137.0
000301292 0247_ $$2doi$$a10.1186/s13058-025-02036-3
000301292 0247_ $$2pmid$$apmid:40355939
000301292 0247_ $$2ISSN$$a1465-5411
000301292 0247_ $$2ISSN$$a1465-542X
000301292 037__ $$aDKFZ-2025-00976
000301292 041__ $$aEnglish
000301292 082__ $$a610
000301292 1001_ $$0P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aHeumann, Philipp$$b0$$eFirst author$$udkfz
000301292 245__ $$aPrognostic value of cancer-related fatigue at the end of radiotherapy for overall survival ≥ 10 years in women with breast cancer.
000301292 260__ $$aLondon$$bBioMed Central$$c2025
000301292 3367_ $$2DRIVER$$aarticle
000301292 3367_ $$2DataCite$$aOutput Types/Journal article
000301292 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747216030_6673
000301292 3367_ $$2BibTeX$$aARTICLE
000301292 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301292 3367_ $$00$$2EndNote$$aJournal Article
000301292 500__ $$a#EA:C020#LA:C020#
000301292 520__ $$aCancer-related fatigue (CRF) is a common symptom in breast cancer patients and survivors, which can substantially impair quality of life. Previous studies suggested that CRF may be associated with poorer survival outcomes, but had limited follow-up duration or insufficient adjustment for established prognostic factors. The aim of this analysis was to assess the prognostic value of CRF at the end of radiotherapy for overall survival in a cohort of women with breast cancer with a median follow-up time of 19 years.Data from the prospective ISE study, which enrolled women with non-metastatic breast cancer between 1998 and 2001, were analysed. Patients did not receive chemotherapy. A vital status follow-up was conducted in 2019. CRF was collected at the end of radiotherapy using the EORTC QLQ-C30 and classified using the threshold of clinical importance. Cox regression models adjusted for CRF, age, body mass index (BMI), tumour size, nodal involvement, grading and receptor status were calculated.Of 437 patients with fatigue assessments, 164 (38%) reported CRF. During 10 years of follow-up, 25 patients without and 27 patients with CRF died. Tumour size, nodal involvement and age were statistically significantly associated with 10-year overall survival. For CRF, a statistically significant effect was observed for ≥ 5 years of follow-up (HR: 2.44), but not within the first 5 years of follow-up (HR: 1.26).CRF assessments at the end of radiotherapy showed prognostic value for long-term survival beyond established factors and could potentially be used to identify patients that require monitoring in risk-adapted aftercare programmes in order to improve survival.
000301292 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000301292 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301292 650_7 $$2Other$$aBreast neoplasms
000301292 650_7 $$2Other$$aFatigue
000301292 650_7 $$2Other$$aPatient reported outcome measures
000301292 650_7 $$2Other$$aRadiotherapy
000301292 650_7 $$2Other$$aSurvival
000301292 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000301292 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b2$$udkfz
000301292 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3
000301292 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b4$$eLast author$$udkfz
000301292 773__ $$0PERI:(DE-600)2041618-0$$a10.1186/s13058-025-02036-3$$gVol. 27, no. 1, p. 76$$n1$$p76$$tBreast cancer research$$v27$$x1465-5411$$y2025
000301292 909CO $$ooai:inrepo02.dkfz.de:301292$$pVDB
000301292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000301292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000301292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000301292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000301292 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000301292 9141_ $$y2025
000301292 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES : 2022$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:36:03Z
000301292 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:36:03Z
000301292 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:36:03Z
000301292 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBREAST CANCER RES : 2022$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-05
000301292 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-05
000301292 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000301292 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000301292 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000301292 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000301292 980__ $$ajournal
000301292 980__ $$aVDB
000301292 980__ $$aI:(DE-He78)C020-20160331
000301292 980__ $$aI:(DE-He78)C060-20160331
000301292 980__ $$aUNRESTRICTED